Pfizer

PFE Healthcare & Pharma 4/10 Medium Risk
4/10
Sector avg: 2.8/10

Pfizer has $64.6B in scheduled debt maturities. While near-term maturities are manageable at $3.0B, the total $64.6B maturity schedule represents a substantial long-term obligation. PFE shows cash covering only 0.4x of $3.0B in near-term maturities. DebtCanary scores PFE at 4/10, indicating moderate refinancing pressure.

Maturity Schedule

Year 1 $3.0B Year 2 $0 Year 3 $0 Year 4 $0 Year 5 $0 Beyond 5 $61.6B
Period Amount Due % of Total
Year 1 (0-12 months) $3.0B 4.6%
Year 2 (12-24 months) N/A N/A
Year 3 (24-36 months) N/A N/A
Year 4 (36-48 months) N/A N/A
Year 5 (48-60 months) N/A N/A
Beyond 5 Years $61.6B 95.4%
Total Scheduled Maturities $64.6B 100.0%

Key Metrics

Total Long-Term Debt
N/A
Near-Term (12mo)
$3.0B
Interest Coverage
N/A
Debt/Equity
0.75
Cash Coverage
0.38x
Operating Income
N/A

Score Components

Component Value Weight
Near-Term Maturity Concentration 4.6% 30%
Interest Coverage Ratio N/A 25%
Debt-to-Equity Ratio 0.75 25%
Cash Coverage of Near-Term Debt 0.38x 20%

Related Companies

Johnson & Johnson
JNJ
1/10
Debt: $41.4B 12mo: $2.0B
AbbVie
ABBV
4/10
Debt: $64.5B 12mo: $6.0B
Merck &
MRK
1/10
Debt: N/A 12mo: $2.6B
Eli Lilly
LLY
3/10
Debt: $29.5B 12mo: $781M
Bristol Myers Squibb
BMY
5/10
Debt: $44.8B 12mo: $2.0B
Amgen
AMGN
6/10
Debt: $54.6B 12mo: $4.6B
Gilead Sciences
GILD
3/10
Debt: $24.9B 12mo: $2.8B
Regeneron Pharmaceuticals
REGN
1/10
Debt: N/A 12mo: N/A

Data Source: Financial data sourced from SEC EDGAR XBRL filings (10-K annual reports). Fiscal period end: 2025-12-31. Filing date: 2026-02-26. Data last fetched: 2026-03-29. Maturity schedules reflect the company's most recently reported debt repayment obligations. Data quality: Partial.
View SEC EDGAR filings for Pfizer →